REMARKS

Claims 1-5, 7, 9-13, 15 and 17-51 presently appear in this case. No claims have yet been examined on the merits in this continuation application. The present amendments are being made in order to place the case into better condition for examination. The final rejection of July 19, 2004, in the parent case, application no. 09/893,348, has now been carefully studied. Prompt consideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to technology developed in the laboratory of the present inventors, which is now known in the art as autoimmune neuroprotection. It has been discovered that secondary neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition can be reduced if steps are taken to cause T cells activated against an NS-specific antigen which, in its native state, is present at the site of secondary neuronal degeneration, to accumulate at the site of neuronal degeneration. The mere presence of these activated T cells at the site of secondary neurodegeneration causes a cytokine response that has a significant effect in reducing the secondary neuronal degeneration. The preferred method of causing the T cells to accumulate at the site of secondary neurodegeneration is either to administer T cells activated against an NS-specific antigen, or an immunogenic or cryptic epitope thereof, or to administer the NS-specific antigen, or the immunogenic or cryptic epitope thereof, itself in such a

way as to cause a T cell response such that T cells become activated against the NS-specific antigen.

In a review of the present application as filed it has been noted that the pages of declaration filed with this case, which were indicated as being copies from parent application no. 09/893,348, are incorrect copies, in part. Attached hereto is a correct copy of the declarations as originally filed in parent application 09/893,348. The attached copies were downloaded from the Image File Wrapper of the file for 09/893,348, so it can be verified that these are, indeed, copies of the actual papers filed in that case. Please substitute the attached copy of the declarations from the parent case for the pages of declaration filed on March 29, 2004.

It has further been noted that the papers as originally filed did not claim benefit of the priority of Israeli application 124550, filed May 19, 1998. Such priority is hereby claimed. A certified copy of said Israeli application was filed as a priority document in grandparent application 09/314,161 on May 19, 1999. The attached Application Data Sheet includes this claim for priority.

The interview among Examiners Bunner and Kunz and the undersigned attorney on July 14, 2004, is hereby gratefully acknowledged. Prior to the interview, a chart was forwarded to the examiners showing evidence establishing the broad range of proven activity for various indications and various peptides and T cells. A slightly revised copy of this

chart is attached hereto. At the interview, the enablement issues were discussed in light of this evidence. Furthermore, the examiners were forwarded a manuscript by two of the present inventors entitled "A Common Vaccine for Fighting Off Neurodegenerative Disorders: Recharging Immunity for Homeostasis." This has now been published at Trends in Pharmacological Sciences, 25:407-12 (2004), a copy of which is attached hereto. This manuscript explains that the selfperpetuating spread of damage that follows acute injury or occurs independently of primary risk factors in any chronic neurodegenerative disorder is commonly viewed as secondary degeneration, and that the mechanisms that underlie the secondary degeneration are the same, regardless of whether they are secondary to the primary insult of an injury or the primary risk factors of a chronic neurodegenerative disorder.

As a result of the interview, the examiners agreed to reconsider the restriction requirement, particularly if additional evidence could be provided establishing that the mechanisms that underlie the secondary degeneration are the same for secondary degeneration following acute injury, as well as chronic neurodegenerative diseases. However, the examiners stated that the independent claims would have to specify the manner of causing the T cells to accumulate at the site of neurodegeneration, such as by specifying the two ways of doing so alternatively, i.e., administering NS-specific antigen or administering T cells activated against NS-specific antigen. Furthermore, the examiners stated that the

enablement objection would be reconsidered if the claims made very clear that the method was for reducing secondary neuronal degeneration that follows neuronal damage caused by an injury or disease.

The arguments presented at the interview will be repeated hereinbelow in the discussion of the various rejections.

In the final rejection of March 4, 2004, the examiner indicated that claims 46-48, 51-52, 54-56 and 59-60 were withdrawn from consideration in view of the restriction requirement. However, as pointed out in the interview discussed above as well as the interview of June 26, 2003, in the parent case, the same mediators are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease. As evidence of this conclusion, the examiner's attention is invited to the attached manuscript of Schwartz and Kipnis, as well as the following two attached references:

- (1) FRIEDLANDER, R.M. "Apoptosis and Caspases in Neurodegenerative Diseases" \underline{N} Engl J Med, 348:1365-75 (2000)
- (2) VAJDA, F.J.E. "Neuroprotection and neurodegenerative disease" <u>J Clin Neurosci</u>, 9:4-8 (2002)

Friedlander is a review that very clearly includes stroke, brain trauma, spinal cord injury, ALS, Parkinson's disease, etc., in the same category of neurodegenerative diseases. Vajda is another review that describes pathological pathways in five different neurodegenerative diseases. It is

believed that these reviews confirm the statements in the Schwartz and Kipnis manuscript that the same factors, i.e, the same mediators, are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease.

Furthermore, as will be discussed below, it is believed that the objections to the generic claims in this case will be overcome by the present amendment specifying two alternative ways of causing the T cells to accumulate at the site of secondary neurodegeneration. As it is believed that these generic claims will now be considered to be allowable, withdrawal of the restriction requirement would be in order with respect to the species that fall within this genus.

Accordingly, reconsideration and withdrawal of the restriction requirement are again respectfully urged.

In the final rejection, the examiner stated that the declaration was defective because of non-initialled or non-dated alterations. The examiner stated that no Application Data Sheet was found attached to the response in the parent case.

Attached hereto is an Application Data Sheet submitting the correct information as to the residence and post office addresses of all of the inventors, which supersedes the data in the originally filed declaration.

Accordingly, it is submitted that in view of this Application Data Sheet, it is no longer necessary to have the declaration re-executed.

In the final rejection in the parent case, the examiner objected to the specification because the status of the patent applications listed in the first paragraph of the specification, as well as at pages 5 and 58, needed to be updated.

The specification has now been amended to update the status of all of these applications. As all of them are now abandoned, this objection can now be withdrawn.

The examiner has maintained the double patenting rejection over the claims of application serial no. 09/218,277. However, as this application has now been abandoned, this double patenting rejection has now become obviated.

Claims 45 and 53 were provisionally rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over claim 38 of copending application no. 09/314,161. This rejection is respectfully traversed.

Application 09/314,161 has now also been abandoned, thus obviating this obviousness type double patenting rejection.

In the final rejection in the parent case, claims 45, 49-50, 53 and 57-58 were rejected under 35 U.S.C. §112, first paragraph, because the specification, while being enabling for a method for promoting recovery from spinal cord injury comprising subcutaneously administering to an individual in need thereof a composition comprising a peptide

derived from Nogo-A, does not reasonably provide enablement for a method for reducing neuronal degeneration caused by the neurodegenerative effects of disease, or for reducing secondary neuronal degeneration that follows the primary neuronal damage of an injury in the central or peripheral nervous system of an individual in need thereof, comprising causing T cells activated against an NS-specific antigen to accumulate at the site of neuronal degeneration. The examiner also stated that the claims also recite that the individual in need is one suffering from an injury that has caused primary neuronal damage. The examiner states that the specification does not enable any person skilled in the art to which it pertains to make or use the invention commensurate in scope with these claims. This rejection is respectfully traversed.

As discussed in the above-mentioned interview, the present amendment now clarifies that it is only directed to reducing secondary neuronal degeneration that follows neuronal damage caused by an injury, disease, condition or disorder. In this regard, reference is made to the present specification at page 8, lines 1-6, which refers to the protection of nervous system tissue "from secondary degeneration which may follow damage caused by injury or disease of the CNS or PNS." This new language, which is supported by the specification as indicated above, now makes clear that the claims are directed only to a method of reducing secondary neuronal degeneration. Furthermore, the Schwartz and Kipnis manuscript and the Friedlander and Vajda publications, discussed above and

attached hereto, establish that the same factors, i.e., the same mediators, are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease. Accordingly, the evidence of record that the present invention is operative to ameliorate the secondary neuronal degeneration following crush-injured CNS nerves, as well as the other evidence of record about the treatment of secondary neurodegenerative effects caused by intraocular pressure (see Bakalash et al, Invest. Opthamal. Vis. Sci. 44:3374-3381 (2003), copy attached) would lead one of ordinary skill in the art reading the present specification to understand that such secondary neuronal degeneration can be treated, regardless of whether it is secondary to various acute injuries or various chronic neurodegenerative diseases, disorders or conditions. Note also that the examples in the present application establish that both T cells activated against an NS-specific antigen and the antigen itself are active in reducing the secondary neurodegenerative effects following optic crush injury and following spinal cord injury. The attached chart also gives references to papers from the laboratory of the present inventors relating to effectiveness of other NSspecific antigens.

Furthermore, it should be understood that applicant's copending application, 09/765,644 (now issued as patent no. 6,844,314 with claims very similar to those herein), is directed to treating the same indications as in

the present invention, except that the T cells that are caused to accumulate at the site of secondary neuronal degeneration are T cells activated by Copolymer 1, rather than an NSspecific antigen. It was discovered that Copolymer 1 acts in a manner similar to NS-specific antigens for the purpose of autoimmune neuroprotection. The laboratory of the present inventor has done many additional tests relating to other indications using Copolymer 1 rather than an NS-specific antigen which, in its native state, is present at the site of secondary neuronal degeneration. As explained by Prof. Schwartz in her presentation at the interview on June 26, 2003, the experimental evidence obtained with Copolymer 1 and T cells activated against Copolymer 1 prove the concept of the present invention in other indications, and thus would lead one of ordinary skill in the art to believe that if an NSspecific antigen which, in its native state is present at the site of secondary neuronal degeneration, is substituted for Copolymer 1 in those indications, it would also work.

With respect to the additional experimentation with Copolymer 1, see also Angelov et al, <u>PNAS</u> 100:4790-4795 (2003) that relates to the treatment of secondary degeneration following facial nerve injury (which is a PNS condition), Kipnis et al, <u>J Neurotrauma</u> 20:559-569 (2003) with respect to the treatment of neurodegeneration following closed head injury, and Schori et al, <u>PNAS</u> 98:3398-3403 (2001) with respect to treatment of secondary neurodegeneration following glutamate toxicity. The examiner's attention is also invited

to WO 03/047500, related to the treatment of secondary degeneration following motor neuron diseases. Another provisional application, 60/518,627, has data relating to the treatment of secondary neurodegeneration following Huntington's disease. This disclosure has been incorporated into a PCT application that has been published as WO 2005/046719, which also has data relating to the treatment of secondary neurodegeneration following Parkinson's disease. Copies of the publications discussed above that are not already of record are attached hereto. All of this evidence confirms applicant's position that the enablement of the present specification would be sufficient to convince those of ordinary skill in the art that the present application would be generally applicable to secondary degeneration following either acute injury or chronic neurodegenerative disease, and therefore that the present claims are indeed commensurate in scope with the enabling disclosure.

In the interview, the examiners stated that a greater amount of evidence of enablement is necessary for a recitation of a specific disease, and so the examiners suggested the deletion of claims such as claims 6, 8, 14 and 16. Accordingly, these dependent claims have now been deleted in view of the potential allowability of the claims from which they depend. This deletion should not be considered as any kind of concession with respect to enablement with respect thereto, and thus the deletion is made without dedication, disclaimer, abandonment, waiver, forfeiture or estoppel. The

examiner's position that the treatment of these specific conditions is not supported by the present specification is duly noted, however, but is obviated by the deletion of these claims.

While the discussion at the interview was directed to the preamble language "a method for reducing secondary neuronal degeneration that follows neuronal damage caused by injury or disease", the presently proposed claims expand "injury or disease" to read "an injury, disease, disorder, or condition". This is being done merely to avoid any confusion as to whether a given indication is truly "a disease". The term "disorder" is supported by the present specification, as it appears, for example, at page 2, line 23; page 37, line 24; page 49, line 17; and page 50, line 15. The term "condition" is supported in the present specification, as it is used, for example, at page 6, line 17; page 38, line 2; and page 59, lines 1, 3, 9 and 11. Accordingly, this language is supported by the specification and should also be permitted.

Another change from the claim language discussed at the interview is in the penultimate administering step of claims 1 and 9. Besides the NS-specific antigen or an immunogenic or cryptic epitope thereof, whose entry and allowability was already agreed to at the interview, the claim has been modified to insert "(iii) a modification of (i) that is immunogenic but not encephalogenic." The present specification clearly states in paragraph [0109] on page 45 that the modification of one or more amino acids at the T cell

receptor binding site is for the purpose of causing the modified peptide to still bind to the T cell receptor such as to be immunogenic, but not encephalitogenic. The subject matter of new claims 50 and 51 are also supported by this paragraph of the specification. Furthermore, new claims 48 and 49 have been added that are specifically directed to the embodiment of treatment of spinal cord injury, as is supported in the present specification, for example, at paragraph [0118] on page 49 of the specification, particularly line 10 of that paragraph.

The examiner has stated that any references that the applicant wishes for the examiner to review and make of record must be supplied in the form of an Information Disclosure Statement pursuant to 37 C.F.R. §1.98(a)(1). It is respectfully submitted, however, that 37 C.F.R. §1.98(a)(1) applies only to Information Disclosure Statements filed under 37 C.F.R. §1.97 and 37 C.F.R. §1.97 and §1.98 only relate to applicant's duty to disclose information material to patentability under 37 C.F.R. §1.56. The references submitted in the previous response in the parent case and those attached hereto are not being submitted as prior art, as they do not necessarily have dates prior to the effective filing date of the present application. They are all being submitted as evidence supporting applicant's position with respect to the enablement rejection, and proving the broad operability of the present invention. Applicants do not require that these documents be listed on the face of the patent, as they are not

In re of Appln. No. 10/810,653
Preliminary Amendment dated March 2, 2006

prior art that is material to patentability. It is sufficient that reference thereto remain in the file history. Applicants are not aware of any rule that states that evidence submitted to support applicants' position with respect to enablement cannot be considered unless submitted on an Information Disclosure Statement pursuant to 37 C.F.R. §1.98(a)(1).

For all of the above reasons, and in view of the amended language of the claims and the additional evidence presented herewith, the present enablement rejection has now been overcome. Reconsideration and withdrawal thereof is therefore respectfully urged.

The present amendment amends the claims substantially in the manner discussed at the interview, and submits the additional information requested by the examiners. Accordingly, it is believed that this amendment places the case into condition for allowance. It is submitted that all of the claims now present in the case clearly define over the references of record and fully comply with 35 U.S.C. §112. Prompt consideration and allowance are therefore earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

D--

Roger L. Browdy

Registration No. 25,618

word?

RLB:rd

Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\B\BENA\EIS-SCHWARTZ2B\PTO\AmendmentA.doc

As a below-named inventor. Thereby decrare that:	original, first
As a below-named inventor. Thereby deciare that. As a below-named inventor. Thereby deciare that. My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the	below) of the
	,
subject matter which is claimed and for which a patent is sought on the inventor entire	
Subject many AND THEIR HERE	

1.5	ntor. I hereby declare that:		on and Power of Attorney	
y residence, post official sole inventor (if on	ly one name is listed below)	at is sought on the invent	my name: and that I believe I am the origin bint inventor (if plural names are listed below ion entitled	al, first) of the
CTIVATED I CELLS	S, NERVOUS SYSTEM-SPE	CIFIC ANTIGENS AND	THE INCOME.	
e specification of whi	ch (check one)			
jxj w U	J.S. Appln No*	: Of	entry into the U.S. national stage of an inter-	national *
(1 n	PCT) application. PCT/ ational stage application rece if known)	; filed ived U.S. Appln. No	entry requested on	*
	* II Kilowii)		(if applicable).	
nd was amended on _	(include dates of amendments u	nder PCT Art. 19 and 34 if	PCT)	
nown by me to be ma	nerial to patentability as defining a priority benefits under 35 U eeder's rights certificate(s).	ed in 57 carrier state of	e Patent and Trademark Office (PTO) all info 365 (b) of any prior foreign application(s) fo CT application which designated at least one	r patent.
other than the U.S., its			Filing Date (MM/DD/YYYY)	
	Application No.	Country Israel	05/19/1998	
_	124500	Israel	05/19/1998	
application designatir date before that of the	124500 priority above. I hereby ident	Israel ify below any foreign ap		al (PCT g a filing
application designating date before that of the No.	oriority above. I hereby identing a country other than the Userliest application from white on-Priority Application No.	ify below any foreign ap United States) or for an i ich foreign priority is clai Country	o5/19/1998 oplication for patent (including an internation nventor's or plant breeder's certificate, having med (if left blank, then there are none): Filing Date (MM/DD/YYYY) visional applications listed below:	al (PCT g a filing
application designating date before that of the No.	oriority above. I hereby identing a country other than the Userliest application from white on-Priority Application No.	ify below any foreign ap Juited States) or for an i ich foreign priority is clai Country	o5/19/1998 uplication for patent (including an internation nventor's or plant breeder's certificate, having med (if left blank, then there are none):	al (PCT g a filing
application designating date before that of the No. I hereby claim the best of the PCT international application is not dispersion.	priority above. I hereby identing a country other than the let earliest application from white on-Priority Application No. Inefit under 35 U.S.C. §119(e) Application PCT/US98/14 Renefit under 35 U.S.C. §120 optication(s) designating the U.S. or PCT owledge the duty to disclose became available between the on:	Israel ify below any foreign application of any United States properties of any United States properties of any prior U.S. non-p.j.S., listed below and, in international application to the PTO all informate filing date of the prior applications.	plication for patent (including an internation inventor's or plant breeder's certificate, having med (if left blank, then there are none): Filing Date (MM/DD/YYYY) visional applications listed below: Date (MM/DD/YYYY) 07/21/1998 rovisional application(s) or under §365(c) of sofar as the subject matter of each of the clain in the manner provided by the first paragrition which is material to patentability as defiapplication and the national or PCT internation	any prions of the aph of 3 ned in 3 ned
I hereby claim the beautiful application is not di U.S.C. §112. I ackn C.F.R. §1.56 which date of this application is application of the date of this application.	nerit under 35 U.S.C. §119(e) Application 19 PCT/US98/14 Application(s) designating the Use optication(s) designating the Use optication of the Use of	Israel ify below any foreign aponited States) or for an inch foreign priority is clais Country of any United States property of any prior U.S. non-polys. Isseed below and, in international application	plication for patent (including an internation inventor's or plant breeder's certificate, having med (if left blank, then there are none): Filing Date (MM/DD/YYYY) visional applications listed below: Date (MM/DD/YYYY) 07/21/1998 rovisional application(s) or under §365(c) of sofar as the subject matter of each of the clain in the manner provided by the first paragrition which is material to patentability as defiapplication and the national or PCT internation Status (patented, pending, abandoned)	any prik ms of th aph of 3 ned in 3 onal filir
I hereby claim the beautiful application is not di U.S.C. \$112. I ackn C.F.R. \$1.56 which date of this application.	priority above. I hereby identing a country other than the let earliest application from white on-Priority Application No. Inefit under 35 U.S.C. §119(e) Application PCT/US98/14 Renefit under 35 U.S.C. §120 optication(s) designating the U.S. or PCT owledge the duty to disclose became available between the on:	Israel ify below any foreign application of any United States properties of any United States properties of any prior U.S. non-p.j.S., listed below and, in international application to the PTO all informate filing date of the prior applications.	plication for patent (including an internation inventor's or plant breeder's certificate, having med (if left blank, then there are none): Filing Date (MM/DD/YYYY) visional applications listed below: Date (MM/DD/YYYY) 07/21/1998 rovisional application(s) or under §365(c) of sofar as the subject matter of each of the clain in the manner provided by the first paragrition which is material to patentability as defiapplication and the national or PCT internation	any prik ms of th aph of 3 ned in 3 onal filir

business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

	Α	ity. Docket: EIS-S	CHWARTZ=2A
Page 2 of 2 Pages Title: <u>ACTIVATED T CELLS, NERVOUS SYSTE</u>	ALSPECIFIC ANTIGENS AND T	THEIR USES	
	. Serial No.		
PCT Application filed	Serial No		
PCT Application fled		ren	amortiona from Wehh
The undersigned hereby authorizes the U.S. Attorned Ben-Ami & Associates as to any action to be taken direct communication between the U.S. Attorneys of whom instructions may be taken, the U.S. Attorneys	or Agents and the undersigned. In or Agents appointed herein will be	the event of a changes so notified by the ur	ge of the persons fron idersigned.
I hereby further declare that all statements made here and belief are believed to be true; and that these state so made are punishable by fine or imprisonment, jeopardize the validity of the application or any pater	or both, under 18 U.S.C. §1001	and that all statement dge that willful false and that such willfu	statements and the like I false statements may
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE		DATE ((2.10-100))
Michal EISENBACH-SCHWARTZ		. r	16,70,200
RESIDENCE		CITIZENSHIP	
Rehovot, Israel		Israeli	
POST OFFICE ADDRESS			
5 Rupin Street, Rehovot 76353, ISRAEL			
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE	:	DATE
Ehud HAUBEN	Ehral Howbern.	10117 11716	16.10.01
RESIDENCE	- 1 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 	CITIZENSHIP	
1		Israeli	
Rehovot, Israel POST OFFICE ADDRESS			
c/o The Weizmann Institute of Science; P.O.	Box 26; Rehovol 76100, ISRAI	EL	
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE	(DATE
			16/10/01
Irun R. COHEN		CITIZENSHIP	
RESIDENCE		Israeli	
Rehovot, Israel			
POST OFFICE ADDRESS			
11 Hankin Street, Rehovot, Israel	INVENTOR'S SIGNATURE		DATE
FULL NAME OF FOURTH JOINT INVENTOR	NATION 3 SIGNATURE		
Pierre BESERMAN		CITIZENSHIP	
RESIDENCE		Israeli	
Moshav Sitriya, Israel			
POST OFFICE ADDRESS			
Moshav Sitriya 76834, Israel			DATE
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATI.
Alon MONSONEGO		CITIZENSHIP	
RESIDENCE		i	
		Israeli	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
Gila MOALEM		CITIZENSHIP	
RESIDENCE			
Rehovot, Israel		Israeli	
POST OFFICE ADDRESS			

ALL INVENTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVENTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVENTORS.

27 Bosel Street, Rehovot, Israel 76405

Atty. Docket: EIS-SCHWARTZ=2A [X] Original [] Substitute OCI 3 1 2001 Page 1 of 2 Pages Combined Declaration for Patent Application and Power of Attorney As a below-named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ACTIVATED T CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES the specification of which (check ons) is attached hereto; was filed in the United States under 35 U.S.C. §111 on June 28, 2001 (X) was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international . filed ز (PCT) application, PCT/_ +; \$371/\$102(c) date national stage application received U.S. Appln. No. (* if known) (if applicable). and was amended on (include dates of amendments under PCT Art. 19 and 34 (FPCT) I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56. I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Filing Date (MM/DD/YYYY) Country Application No. 05/19/1998 Israel 124500 If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCI) application designating a country other than the United States) or for an inventor's or plant breader's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none): Filing Date (MM/DD/YYYY) Non-Priority Application No. I hereby claim the benefit under 35 U.S.C. §119(c) of any United States provisional applications listed below: Filing Date (MM/DD/YYYY) Application No. 07/21/1998 PCT/US98/14715

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. \$1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Status (patented, pending, abandoned) Filing Date (MM/DD/YYYY) Application No. Pending 05/19/1999 09/314,161 Pending 12/22/1998

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

·						
•			c_a Rī	s-schwa	RT2)=2A
		Atty. Doc	NOC.			
••		TUGENS AND THEIR U	000			
a 2 of 2 Pages E ACTIVATED I COLLS NERVOUS SYSTEM-SP Application filed lane 28, 2001	Rectal N	io				
ACTIVATED T CELLS. NERVIUS DATE Application filed Inno 28, 2001 A	Sorial N	ia		امس	E	on Wash
Application filed time 28, 2001 Application filed Application filed to undersigned beachy authorizes the U.S. Arteries of the water signed beachy authorizes the U.S. Arteries of the Amortan between the U.S. Attorneys or Application between the U.S. Attorneys or Applications and the U.S. Attorneys or Applications between the U.S. Attorneys or Applications and the U.S. Attorneys or Applications are applications and the U.S. Attorneys or Applications are applications and the U.S. Attorneys or Applications an		1 Country to DOCCO	mq bik	A MINDO	للعوال	on without
Application likes	Agents W	pointed the demands Office	Legator	AMARIE CE I	be pe	moor from
havely withorizes the U.S. Arter in the	u U.S. Pat	and and transfer in the or	THE PARTY	the orners	إعطا	<u>.</u>
unitraligies between states at the say scales to American or Ag		in the same will be so or	SUMOT AN			made on
PORTUGE AND ADMINISTRATION OF PARTIES AND ADMINISTRATION OF PARTIE			4 4			
uniteraigned bereby authorizes the U.S. Attorneys of Learning Associated as to any section to be taken in the Learning action between the U.S. Attorneys or Ag our terrestrians may be taken, the U.S. Attorneys or A con instructions may be taken, the U.S. Attorneys or A constructions may be taken, the U.S. Attorneys or A construction and belief are believed to be true; and if the constant and belief are believed to be true; and if the constant and belief are believed to be true; and if the constant and belief are believed to be true; and if the constant and belief are believed as a maintachia by in-	min of Mi	CHE PURPLECED AND A	ich the i	CIDAMOON	10Bt	and Alley
the declare that all givening the said	that these t	risticance is both under 1	g USC.	amo.	-	
sereby fixther bedief are believed to be the by fin	n os justicis	CHILDREN SELDED BECOME				
Ami & Associated between the U.S. Amorroys or so not communication between the U.S. Amorroys or the instructions may be taken, the U.S. Amorroys or for instructions may be taken, the U.S. Amorroys or for instruction made between further declare that all statements made be true; and the like are believed to be true; and the statements and the like as made are punishable by financiants and the like as made are punishable by financiants and the like as made are punishable by financiants and the like as made are punishable by financiants and the like as made are punishable by financiants.	ication of	TA Permana			<u></u>	
Denoted and John of the Assessment of the Assess				1 "		
	DIVENT	TOP'S SIGNATURE				
FULL NAME OF FIRST DEVENTOR	l		CHUZEO	SHIP		1
MICHAELE STRET SEVERICE MICHAEL EISENBACH SCHWARTZ		-	forseli			
MICHA DISTANCE				. –		ļ
Rehovot, Israel		. **				
POST OFFICE ADDRESS		The second liver with the second	-	{1	DATE	1
	DIVE	STUR'S STOWATURE		المسيد		
S KILDIN STORY OF MECONS INVENTOR	1		1 000	DENE P		
MAL NAME OF SECOND		-	Term			
Elmid PLALIBEN			_			
RESIDENCE		****	٦.			-
Rehovet, Israel	Page 26: 1	Chovot 76100, 188745	-		BAS	5
Rehovot, Israel FOST OFFICE ADDRESS C'O The Weizmann Institute of Science P.O.	200	POTCH'S SUPPLYURE				
CO THE WEIGHT THE SENT DIVERTOR	1-		100	THING		
FULL NAME OF THE PARTY				seli		
Irun R. COHEN			ستسلسد			
SESTIMAN	سسند			_		
Rebovot, Israel			-		10	ASE
POST OFFICE ADDRESS 11 Hankin Street, Rehavot, Israel		RYENTOR'S STONATURE	_e		14	0.01
FOU. NAME OF FOURTH MUST DEVENUE.		AT DUCK		THEESERP		
FOU. NAME OF POUR BACK	سلسسيہ		15	arachi_		
Pinte BESERMAN	•		<u>_</u>	N SOM		
TOTAL STATE OF THE						
Kibbutz Chabitz Chahn, israel					7	DATE
FOR OFFICE APPEARS Kibbute Chaftee Chaim 76817, Israel		DIVERTOR'S SENIATURE	-		- 1	
Kibbutz Chafele Chang	-	UlAbelian a		CHI COLL COLL COLL COLL COLL COLL COLL COL		
KINT NAME OF ABILE TON DIVENTOR			_ [ierseli		
Alm MONSONEGO				Falsen		
RESIDENCE						
		•		_		DATE
POST OFFICE ATOMESS		DEVENTOR'S SURGETURE	1	_		}
		BANKER, P. STREET				1
POLLANSE OF SOCIET DON'T DIVENTOR		<u> </u>		O TUPO S	œ	
GIB MOALEM				Israeli		
RESUMENCE						
						-
Rehavot, Israel FOST GENERAL REMOVAL, Israel 7540: 27 Bosel Street, Rehavot, Israel 7540:	c		-		-	THE PARTY PARTY.
27 Bosel Street, Rebowd, Israel 7840:	-		THE DATE AND	D NOT SATED I	الملام	N. 4-ali
Ti Bosei Saran	ANTON MORE	CONTROL ME NATIONALISM NATIONAL PROPERTY AND	PLAN BY AT	Elektrick and		
THE PARTY AND PARTY AND PARTY.	IN ROOM. ALL	trose				

all undertable substancial and declaration deposits durings. All interscript best is lightly for all divorces. No alteractions can be had an tip included the best and all filling of declaration has the light of all divorces.

Combined Declaration for Patent Application and Power of Attorney If a below-named inventor, I hereby declare that: Ay residence, port office address and citizanship are as stated below next to my name; and that I balieve I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the abeliance and for which a patent is sought on the invention entitled ubject matter which is claimed and for which a patent is sought on the invention entitled CTIVATED T CEULS, NREVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES. Is a statehold hearth; If is attached hearth; If was filled in the U.S. under 35 U.S.C. §111 on June 28, 2001. It was filled in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international entry requested on (PCT) application, PCT) In advant great application, PCT/ In advant great application received U.S. Appla. No. (if applicable). (if applicable). (include dates of amendments under PCT Art. 19 and 34 (PCT) I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56. I hereby claim foreign priority benefits under 35 U.S.C. §5 119 (a)-(3) and 365 (b) of any prior foreign application(6) for patent, inventor's or plant breeder's rights certificate, (c), or under §355(a) of any PCT application for patent fineduling an international (PCT) Application No. County Piling Date (OM/DD/YYYY) Application No. County Filing Date (OM/DD/YYYY) Application No. PCT USSSP14715 Filing Date (OM/DD/YYYY) Application No. PCT international application for mater as subject unater of each of the claims of this application in the manner proteid by the first paragraphy of 31 SUSC. §11.5 (a) 10.0 (AM/DD/YYYY) Application No. PCT U	•		•	······································	3
Combined Declaration for Patent Application and Power of Attorney at a below-named inventor, I hereby declare that: Ay residence, port office address and citizanship are as stated below next to my name; and that I balieve I am the original, first and solic inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the ubject mater which is claimed and for which a patent is sought on the invention entitled below) of the ubject mater which is claimed and for which a patent is sought on the invention entitled below) of the ubject mater which is claimed and for which a patent is sought on the invention entitled below) of the ubject mater which is claimed and for which a patent is sought on the invention entitled below) of the ubject material state of the triple of the patent into the U.S. national stage of an international into the U.S. national stage of an international entry requested on (PCT) application, PCTV is fled entry requested on (PCT) and and stage application received U.S. Applic. No. (If explicable). In have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information amendment referred to be material to patentability as defined in 37 C.F.R. §1.56. I hereby claim foreign priority benefits under 35 U.S.C. §8 119 (a)-(d) and 365 (b) of any prior foreign application (S) or patent, application and patentability above. I bereby identify below my foreign application for patent fine building an international papilication and the before that of the entitlest application from which foreign prior	<u>_</u>	rvi Original []	Substitute OCT 3 1 2	001 Atty. Docket: EIS-SCHWAR12-22	1
As a below-named inventor, I hereby declars that: Ay residence, post office address and citizanship are as stated below next to my name; and that I believe I am the original, first Ay residence, post office address and citizanship are as stated below next to my name; and that I believe I am the original, first and joint inventor (if plural names are listed below) of the nd sole inventor (if only one name is listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the number of number of the number of numbers of number of number of number of number of numbers of number of numbers of number of numbers of	Page 1 of 2 Pages	[X] Ongain	\2.	and Power of Attorney	
As a below-named inventor, I hereby declars that: Ay residence, post office address and citizanship are as stated below next to my name; and that I believe I am the original, first Ay residence, post office address and citizanship are as stated below next to my name; and that I believe I am the original, first and joint inventor (if plural names are listed below) of the nd sole inventor (if only one name is listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the nd sole inventor (if plural names are listed below) of the number of number of the number of numbers of number of number of number of number of numbers of number of numbers of number of numbers of	Combin	ed Declaration for	Patent Applica	toward rower of record	
Ay residence, port office address and climated below) or an original, first and joint inventor (if plural names are also as the contents of only one name is listed below) or an original, first and joint inventor of only one as a climated below) or an original, first and joint inventor of collection of which (check one) [1] is attached hereto; [2] is attached hereto; [3] was filed in the United States under 35 U.S.C. §111 on June 28. 2001 [4] Was filed in the United States under 35 U.S.C. §111 on June 28. 2001 [5] U.S. Appla No. [6] washvill be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international range application, PCT/ national stage application PCT/ national stage application received U.S. Appla. No. [6] (Fet paplicable). [6] (Fet is hown) [6] (Fet is hown) [7] (Fet is hown) [8] (Fet is hown) [9] (Fe	1 lanes	tor Thereby declars that:		the original	first
and sole inventor ir only vite a man of fer which a patent is sought on the invention entities CTIVATED T CELLS. NERVOUR SYSTEM-SPECIFIC ANTIGENS AND THEIR USES In attached hereto; In a stached hereto;	Au encidence, post offic	e address and Citizmiship a	re as stated below next	oint inventor (if plural names are listed below) o	fthe
where where it stands to the second process of the specification of which (check one) [] is strached hereto; [X] was fitted in the United States under 35 U.S.C. §111 on June 28, 2001 U.S. Appla. No	and and a inventor DI ODA	A Offic Witness and and and	the sevents and the invest	aon endreo	
is attached hereto; [X] is attached hereto; [X] was filed in the United States under 35 U.S.C. §111 on June 28, 2001 U.S. Applin. No. U.S. Applin. No. U.S. Applin. No. (PCT) application, PCTV interest stage application received U.S. Applin. No. (** if known) and was amended on (** if known) (if applicable). (** if known) by me to be material to patentability as defined in 37 C.FR. §1.56. Inverted to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information which designated at least one country inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Application No. Laston Application No. Country Application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which forcign priority is claimed (if left blank, then there are none): Application No. PCT/US98/14715 I hereby claim the benefit under 35 U.S.C. §119(c) of any United States provisional application(s) or under §355(c) of any prior U.S. non-provisional application(s) or under §355(c) of any	ubject matter which is o	lairned and lor which a pass	CIFIC ANTIGENS AN	D THEIR USES	-
is attached hereto; [X] is attached hereto; [X] was filed in the United States under 35 U.S.C. §111 on June 28, 2001 U.S. Applin. No. U.S. Applin. No. U.S. Applin. No. (PCT) application, PCTV interest stage application received U.S. Applin. No. (** if known) and was amended on (** if known) (if applicable). (** if known) by me to be material to patentability as defined in 37 C.FR. §1.56. Inverted to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information amendment referred to above; and I secknowledge the duty to disclose to the Pakent and Trademark Office (PTO) all information which designated at least one country inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Application No. Laston Application No. Country Application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing date before that of the earliest application from which forcign priority is claimed (if left blank, then there are none): Application No. PCT/US98/14715 I hereby claim the benefit under 35 U.S.C. §119(c) of any United States provisional application(s) or under §355(c) of any prior U.S. non-provisional application(s) or under §355(c) of any	ACTIVATED T CELLS	NEKAGINE STERESTO	20000		
Was filed in the United States under 35 U.S.C. §371 by entry into the U.S. national stage of an international was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage application. PCT/ papilication, PCT/ papilication received U.S. Appln. No	he specification of whic	h (check one)			
U.S. Appln. No		and A to At a Timeteral States	under 35 U.S.C. §111 or	June 28. 2001 88	
national stage application received U.S. Appla. No					ional
national stage application received U.S. Appla. No	r 1 W	s/will be filed in the U.S.	mder 35 U.S.C. §3/1 b	, entry requested on	";
(if applicable). (include datas of amendments under PCT Art. 19 and 34 (FPCT) (include datas of amendments under PCT Art. 19 and 34 (FPCT) (include datas of amendments under PCT Art. 19 and 34 (FPCT) (include datas of amendments of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information mown by me to be material to patentiability as defined in 37 C.F.R. § 1.56. (I hereby claim foreign priority benefits under 35 U.S.C. § § 119 (a)-(d) and 365 (b) of any prior foreign applications(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Application No. 124500 17 I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designation accountry other than the United States provisional applications listed below: Non-Priority Application No. Country Piling Date (MM/DD/YYYY) Application No. PCT/US98/14715 O7/21/1998 I hereby claim the benefit under 35 U.S.C. § 120 of any prior U.S. non-provisional applications listed below: PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application and the national or PCT international filing date of this appl	(P	CT) application, PCT/	eived U.S. Appla. No.	*; §371/§102(c) datc	
have reviewed and understand the contents tander PCT Art. 19 and 34 (PCT) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any inconductive to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information mown by me to be material to patentalitify as defined in 37 C.F.R. §1.56. (I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Application No.	105	tional stage application for			
have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any mendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information mown by me to be material to patentability as defined in 37 C.F.R. §1.56. hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, hereby claim the U.S., listed below: Application No.	•			(if applicable).	
have reviewed and understand the contents of the above-identified specification, including the blank, mendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information mown by me to be material to patentability as defined in 37 C.F.R. §1.56. Thereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Application No. 124500 124600 124600 124600 124600 124600 124600 124600 124600 124600	nd was amended on	Gralinia dates of amendments t	mder PCT Art. 19 and 34 t	PCT)	
Incredit in about the patentability as defined in 37 C.F.R. §1.56. In the poly claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any P.C.T. application which designated at least one country inventor's or plant breeder's rights certificate(s), or under §365(a) of any P.C.T. application which designated at least one country other than the U.S., listed below: Application No.		(DIETURS LILLA V	4	cification, including the claims, as amended by	/ any
Application No. Israel O5/19/1998 If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States or for an inventor's or plant breeder's certificate, having a filing before that of the earliest application No. Country Piling Date (MM/DD/YYYY) Application No. Filing Date (MM/DD/YYYY) O7/21/1998 I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information and the national or PCT international filing date of this application: Pending	amendment referred to	erial to patentability as defin	acd in 37 C.F.R. §1.56.	a - Hastian(e) for the	atent.
If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application designating a country other than the United States) or for an inventor's or plant breeder's certificate, having a filing application of the earliest application from which foreign priority is claimed (if left blank, then there are none): Non-Priority Application No.	INVIOUNTATION OF THEIR U. C.	1401 D 116555			
If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCT) application designating a country other than the United States) or for an inventor's or plant breader's excitificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none): Non-Priority Application No. Country Piling Date (MM/DD/YYYY) Non-Priority Application No. Filing Date (MM/DD/YYYY) Application No. Filing Date (MM/DD/YYYY) PCT/US98/14715 O7/21/1998 I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined of this application: Publication No. Publication: Publication PCT international filing date of this application: PCT international filing date of this application: PCT international filing date of this application: PCT international paragraph PCT international paragraph PCT international filing date of this application: PCT international paragraph PCT international pa	Office man and olari		Country	Lijud Dat (Waaday * * * * * * * * * * * * * * * * * * *	
Application designating a carliest application from which foreign priority is claimed in the total place of the earliest application No. Country Piling Date (MM/DD/YYYY) Application No. PCT/US98/14715 PCT/US98/14715 I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this PCT international application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information and the national or PCT international filing C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international date of this application: Pending		1.40	Israel	03/83/1022	
I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application which is material to patentability as defined in 37 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §156 which became available between the filing date of the prior application and the national or PCT international filing C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application: Application No. Filing Date (MM/DD/YYYY) Pending	date before that of the	earliest application from wh	ich foreign priority is cis	pplication for patent (including an international (inventor's or plant breeder's certificate, having a imed (if left blank, then there are none): Piling Date (MM/DD/YYYY)	(PCT) filing
I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 application is not disclosed in such U.S. or PCT international application which is material to patentability as defined in 37 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §156 which became available between the filing date of the prior application and the national or PCT international filing C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application: Application No. Filing Date (MM/DD/YYYY) Pending	 -	26 II S C 8119(c)	of any United States pr	ovisional applications listed below:	
I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §156 which became available between the filing date of the prior application and the national or PCT international filing date of this application: Application No. Filing Date (MM/DD/YYYY) Status (patented, pending, abandoned)	I hereby claim the ben	offt under 35 U.B.C. Valley	No Filio	Date (MM/DD/YYYY)	
I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 u.S.C. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application: Application No. Filing Date (MM/DD/YYYY) Pending		дрионии. рстл1998/14		07/21/1998	
application is not disclosed in such U.S. or PCT international application in the mainter production as application is not disclosed in such U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 U.S.C. §115, i acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37			= :		
date of this application. Status (patented, pending, abandoned) Pending Date (MM/DD/YYYY) Pending	application is not dis U.S.C. §112, I ackno C.F.R. §1.56 which b	closed in such U.S. or PCI wledge the duty to disclose ecame available between the	r international application	in in the mainter provided in the material to patentability as defined application and the national or PCT international application and the national application application and the national application and the national application and the national application application and the national application application and the national application and the national application application and the national application application application application and the national application ap	in 37
	date of this application	n.		Status (patented, pending, abandoned)	
	Applic	ation No.		Pending	

05/19/1999 09/314,161 Pending 12/22/1998 As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

Page 2 of 2 Pages	Atty	. Docket: KIS-	SCHWARTZ=2A
Title: ACTIVATED T CELLS. NERVOUS SYSTEM-SP	ELIFICANTIGENS AND THRUE	1363	
U.S. Application filed June 28, 2001	Senai No		
PCT Application filed	, Senat No		
The undersigned hereby authorizes the U.S. Attorney Webb Ren-Ami & Associates as to any action to be take without direct communication between the U.S. Attorneysons from whom instructions may be taken, the lundersigned.	en in the U.S. Parent and Trader usys or Agents and the undersig U.S. Antomays or Agents appoin	mirk Office regarded. In the eventual ted herein will	ent of a change of the so notified by the so notified by the so notified by the sound of the sou
I hereby further declare that all statements made har information and belief are believed to be true; and it statements and the like so made are punishable by it willful false statements may jeopardize the validity of	hat these statements were made fine or imprisonment, or both, t	with the knowled index 18 U.S.C.	THE WILLIAM THE
FULL NAME OF VIRST INVENTOR	INVENTOR'S SIGNATURE		DATE
Michal EISENBACH-SCHWARTZ	<u> </u>	CTUZENSHIP	<u> </u>
RESIDENCE			
Rehovet, Israel		Israeli	
POST OFFICE ADDRESS			ļ
5 Rupin Street, Rehovot 76353, ISRAEL			
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
Bhud HAUBEN			L
DESTDENCE		CILINENAMA	1
Rehovot Israel		Isracli	
POST OFFICE ADDRESS	,		ì
c/o The Weizmann Institute of Science; P.O. Box	c 26; Rebovot 76100, ISRAEL		
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S STEVATURE		DATE
Irun R. COHEN		CITIZENEELP	
RESIDENCE		Igraeli	
Rehovot, Israel		- AMEDIA	
POST OFFICE ADDRESS			ļ
11 Hankin Street, Rehovot, Israel			DATE
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE	·	
Piecre BESERMAN	<u> </u>	CITIZENSHIP	L
RESIDENCE		Israeli	1
Moshav Sitriya, Israel		INIMELL	
POST OFFICE ADDRESS			
Moshav Sitriya 76834, Israel			
FULL NAME OF FIFTH FORT INVENTOR. Alon MONSONEGO	INVENTOR'S STRINATURE	_	Oct. 16.01
MANDENCE .	1	CITIZENSHIP	
RLOYOF ISRAEL	•	Israeli	
POST OFFICE ADDRESS	77110	(Ben-	Varal)
Kelar Hanoar Ben-SA	PMEN TSILE INVENTOR'S SIGNATURE	(BED-	DATE
Gila MOALEM			
RENIDENCE		CITZENSED	
Rehovot, Israel		Isracli	
POST OFFICE ADDRESS			
27 Boral Street Rehovet Israel 76405	•		

Atty. Docket: KIS-SCHWARTZ=2A

ALL IMPORTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE ECONOL. ALL ALTERATIONS MUST BE ESTIMATED AND PATED BY ALL INVIDITION; WICH, TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE RECLARATION BE SUCKED. ALL FACES OF DECLARATION MANY DESIGNS OF ALL DIVERTORS.

Page 1 of 2 Pages [X] Original [] Substitute

Combined Declaration for Patent Application and Power of Attorney

Com	Dinea 200			
As a below-named in	nventor, I hereby declars th	at:	a to my name; and that I believe I am the original, first digital inventor (if plural names are listed below) of the	
My residence, post	office address and citizens	hip are as stated below nex	a to my name; and that I believe I all the below) of the djoint inventor (if plural names are listed below) of the entitled	
and sole inventor (1)	Only one name	is cought on the inv	ention entitled	
subject matter which	f only one name is listed be is claimed and for which a	paicin is sought on the same	ND THEIR USES	
ACTIVATED T CE	LLS, NERVOUS SYSTEM	-265 (the our residence		
the specification of	which (check one)			
[]	is attached hereto;		on <u>June 28. 2001</u>	
(x)	1 I- No	*: or		
	U.S. Appln. No.	J.S. under 35 U.S.C. §371	by entry into the U.S. national stage of an international entry requested on	
[]	(PCT) application, PCT/	filed	entry into the U.S. nanonal stage of all distributions of the party requested on	
	national stage application	a received U.S. Appln. No.	1 321113111	
	(* if known)	•	(is conlicable).	
and was amended o	M	ents under PCT Art. 19 and 34	(It submound)	
MIN WES EMORIOUS	(prolude dates of amendm	ients under PCT Art. 19 and 34	Vis vid behave as expended by 80V	
amendment referre	nd understand the content d to above; and I acknowle	edge the duty to disclose to	the Patent and Trademark Office (PTO) all information	
known by me to be	HINTELINE OF Departments		a series confication(s) for patent.	
INVENTATE OF DIAM	DICECO STATEMENT COLUMN	(s), or under §365(a) of any	nd 365 (b) of any prior foreign application(s) for patent, y PCT application which designated at least one country	
other than the U.S.	, listed below:		Filing Date (MM/DD/YYYY)	
	Application No.	Country	05/19/1998	
	124500	Israel	9313710770	
date before that of	the earliest application from Non-Priority Application No.	_	application for patent (including at interest, having a filing in inventor's or plant breeder's certificate, having a filing slaimed (if left blank, then there are none): Filing Date (MM/DD/YYYY)	
_				•
_				
I haveby claim file	benefit under 35 U.S.C. §1	19(c) of any United States P	provisional applications listed below:	
I nereny claim are	Applica	mon No.		
		98/14715	07/21/1993	
application is not U.S.C. §112, I at C.F.R. §1.56 whi	application of temperature in such U.S. or knowledge the duty to disch became available between	PCT international applicat	a-provisional application(s) or under §365(e) of any prior insofar as the subject matter of each of the claims of this tion in the manner provided by the first paragraph of 35 nation which is material to patentability as defined in 37 or application and the national or PCT international filing	
date of this applic		Filing Date (MM/DD/YYYY	Status (patented, pending, abandoned)	
	plication No.	05/19/1999	t enough	
	09/314,161	22/22/100f	Pending	
		following registered pract	titioners to prosecute this application and to transact all	•
onstress to the re	4 11 of the new	ctitioners associated with	Customer Number 001444	
	All of rice hea	La Judit Contamas Num	ther 001444, which is presently:	
Direct all corresp	ondence to the address asso	CIRLEG WIR CUSTOMER 1441	aber 001444, which is presently:	
		DROWNY AND NEI	MAKA FILL.	

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

	Page 2 of 2 Pages			SCHWARIZPZA
	THE ACTIVATED T CELLS NERVOUS SYST	TRM-SPECIFIC ANTIGENS AND T	HRIR LISES	
	U.S. Application filed June 28, 2001	Seriel Na		
	PCT Application filed	Serial No.	·.	•
·	•		•	
•	The ordersigned hereby authorizes the U.S. Atom <u>Rev-Ami & Associans</u> as so any action to be take direct communication between the U.S. Atomocys whom instructions may be taken, the U.S. Atomocys	on the class recent and the professional. The	the exemt of a city	mee of the persons the
•	•	•		
·	I hereby further decisive that all statements made he and believed to be true; and that these states are purjetable by these or imprisonment, important made he imprisonment, important or any period of the opplication of opplication of the opplication opplication opplication opplication opplication opplication opplication opplication opplic	temente wan made with the knowled oe buth, mader 18 U.S.C. § 100) s		SO PARTICIONELLES BLIFT FUR IN
	FIEL NAME OF FREST DIVENTOR	DIVENTOR'S SIGNATURE	•	DATE .
		TAKENICE BEIMONING		\
	Michai Eisenbach-Schwartz	<u> </u>		J
•	- MINIDENCE	•	CTTEDISTIP .	
	Rehovot, Israel		Israeli	
	POST OFFICE ADDRESS			
	5 Rupin Street, Rehovot 76353, ISRAEL	·. ·		
r	FIEL NAME OP SECOND LODIT DIVENTOR	DIVENTOR'S SIGNATULE	-	DATE
		THE BATCHE & SPECIAL PROPERTY.		1
• •	Shed MAUBEN			إحسسنا
	MEDERCE .	• •	CULTBER	1
· · ·	Rehavos, Jurgei		lerseli	·
	NOST DEFICE ADDRESS			•
	To The Weisman Institute of Science; P.O.	Box 26: Rehovet 76100, INRAEL		· j
	FULL NAME OF THEIR DOINT BYZEKTOR	DIVERTOR'S SHINKTURE		DATE
	In R. COHEN	traditor a delectors	• .	1
•			7.00	J
, •	RENDENCE		CULTABION	ł
	Rehovet, Israel	<u> </u>	Israeli ·	
•	POST OFFICE ADDRESS			
	11 Hankin Street, Rehovet, James		_ • . <u>• · · · · · · · · · · · · · · · · · · </u>	
	PULL NAME OF FOURTH JOINT INVENTOR	DEVENTOR'S EXCHATURE		DATE
•	Plane BRSERMAN	20,21100 22,0100	•	}
• •	ZERDEKE		1	
		•	CITZENSIU	
	Kibbutz Chafetz Chelm, Israel		ľareli .	
	POST OFFICE ADDITION		•	- 1
•	Kibbutz Chairtz Chaim 76817, Israel		<u>.</u>	•
	PULL NAME OF REPOSTORY INVENTOR	DIVERTOR'S SERVATURE		DATE
	Alos MONSONEGO			1
	RPRODUCE		CITZBION ·	1
	· ·	• •		
			Israeli '	
•	POST CEPTICE ADORRES	·	•	: 1
• •		<u>-</u> _••		
· ·	FULL HALE OF EDGE PORT INVENTOR .	DIVESTOR'S EXPRATURE	-1-	DATE .
	GIIS MOALEM	- June	2/2	October 15.01
	BESPICE	2300	CITIZENSIES*	TARKKE IN ST.
01		•	1	· • • 1:
Tetan- ligge	Beloves, Servel		Taraéli	
7	POST OFFICE ADDRESS	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	٠ - بـ	44.
•	STRONG PROPERTY 21	Orlar Stroot Itta	h- Tieva.	47772

ALL BANGALORS MITEL SENSEN, VALVENTION WAS INCOMEDIATED SELECT MINISTER OF PROPERTY OF SECURITY OF SECURITY SELECT SECURITY SECURITY SELECT SECURITY SECURITY SELECT SECURITY SECUR

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.